We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$15.2B
AUM Growth
+$366M
Cap. Flow
+$107M
Cap. Flow %
0.7%
Top 10 Hldgs %
31.7%
Holding
1,371
New
97
Increased
870
Reduced
195
Closed
30

Top Sells

Rank Stock Value
1
EQIX icon
Equinix
EQIX
+$266M
2
SUI icon
Sun Communities
SUI
+$169M
3
EXR icon
Extra Space Storage
EXR
+$143M
4
AMT icon
American Tower
AMT
+$103M
5
KRC icon
Kilroy Realty
KRC
+$102M

Sector Composition

Rank Sector Weight
1 Real Estate 55.88%
2 Technology 9.18%
3 Communication Services 4.61%
4 Consumer Discretionary 4.25%
5 Financials 3.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SMMT icon
1226
Summit Therapeutics
SMMT
$10B
$2K ﹤0.01%
334
+179
+115% +$1.28K
SPRO icon
1227
Spero Therapeutics
SPRO
$69.5M
$2K ﹤0.01%
110
+59
+116% +$947
XENE icon
1228
Xenon Pharmaceuticals
XENE
$6.28B
$2K ﹤0.01%
141
+75
+114% +$1.3K
PETQ
1229
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$2K ﹤0.01%
99
+44
+80% +$1.33K
EGRX
1230
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2K ﹤0.01%
30
GTHX
1231
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2K ﹤0.01%
145
+73
+101% +$1.19K
KDNY
1232
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2K ﹤0.01%
153
+74
+94% +$974
CLVS
1233
DELISTED
Clovis Oncology, Inc.
CLVS
$2K ﹤0.01%
406
+240
+145% +$1.16K
ABUS icon
1234
Arbutus Biopharma
ABUS
$871M
$1K ﹤0.01%
160
ACIU icon
1235
AC Immune
ACIU
$236M
$1K ﹤0.01%
158
AKBA icon
1236
Akebia Therapeutics
AKBA
$341M
$1K ﹤0.01%
316
ANIP icon
1237
ANI Pharmaceuticals
ANIP
$1.84B
$1K ﹤0.01%
27
APLT
1238
DELISTED
Applied Therapeutics
APLT
$1K ﹤0.01%
42
AVDL
1239
DELISTED
Avadel Pharmaceuticals
AVDL
$1K ﹤0.01%
120
BDTX icon
1240
Black Diamond Therapeutics
BDTX
$101M
$1K ﹤0.01%
68
CABA icon
1241
Cabaletta Bio
CABA
$445M
$1K ﹤0.01%
45
CGEN icon
1242
Compugen
CGEN
$214M
$1K ﹤0.01%
156
CLLS
1243
Cellectis
CLLS
$286M
$1K ﹤0.01%
40
CTMX icon
1244
CytomX Therapeutics
CTMX
$701M
$1K ﹤0.01%
102
DNTH icon
1245
Dianthus Therapeutics
DNTH
$5.55B
$1K ﹤0.01%
7
ESPR
1246
DELISTED
Esperion Therapeutics
ESPR
$1K ﹤0.01%
52
GERN icon
1247
Geron
GERN
$930M
$1K ﹤0.01%
684
INZY
1248
DELISTED
Inozyme Pharma
INZY
$1K ﹤0.01%
44
KALV
1249
DELISTED
KalVista Pharmaceuticals
KALV
$1K ﹤0.01%
46
KNSA icon
1250
Kiniksa Pharmaceuticals
KNSA
$6.11B
$1K ﹤0.01%
60

Similar funds

Daiwa Securities Group's Q3 2021 Portfolio in Review

As of Q3 2021, Daiwa Securities Group held 1,371 positions worth $15.2B, up 2.5% from $14.8B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Daiwa Securities Group's Q3 2021 filing shows 97 new, 870 increased, 195 reduced and 30 closed positions. Its largest new stake was Global X Cloud Computing ETF: 500,000 shares worth $14.6M. The largest sale was Equinix, an estimated $266M.

By sector, the portfolio is most concentrated in Real Estate at 56% of assets, down from 59% a quarter earlier, followed by Technology and Communication Services.

  • Daiwa Securities Group's largest Q3 2021 buy was Global X Cloud Computing ETF: 500,000 shares worth $14.6M.
  • Daiwa Securities Group added most to Invitation Homes in Q3 2021, an estimated $175M increase.
  • Daiwa Securities Group's biggest Q3 2021 reduction was Equinix, cutting an estimated $266M.
  • Daiwa Securities Group fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $3.09M.
  • Daiwa Securities Group's ten largest holdings make up 32% of its $15.2B portfolio in Q3 2021.
  • Daiwa Securities Group opened 97 new positions and closed 30 in Q3 2021.
  • Daiwa Securities Group's portfolio value rose 2.5% quarter-over-quarter to $15.2B.

Based on Daiwa Securities Group's 13F filing for Q3 2021, filed 5 Nov 2021.